Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Chanan-Khan A et al. - Fatigue and sensory neuropathy were the most common side effects noted. The authors observe that VDT is an effective steroid-free regimen with ability to induce durable remission even in patients with refractory myeloma.


Today in Myeloproliferative Dz...keeping you current

Bortezomib: a new therapeutic option for POEMS syndrome
European Journal of Haematology, 10/13/09

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial : The Lancet Oncology
The Lancet Oncology - Online First, 10/23/09

Prognostic molecular markers in myelodysplastic syndromes
Expert Review of Hematology, 10/22/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address